Clinical Trial Update: Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of ShigETEC, a live attenuated oral vaccine, to prevent Shigella and Enterotoxigenic Escherichia coli infe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection
• Shigellosis

Drugs mentioned

• ShigETEC (ShigETEC vaccine (live attenuated))

Snippet

Sponsor: Eveliqure Biotechnologies GmbH | Conditions: Shigella | Phase 2 | Status: RECRUITING